Upstream Biosciences Inc. ~ Press Releases

PRESS RELEASE - MAY 14th, 2007

Upstream Biosciences Inc. Appoints Edward Kiruluta To Scientific Advisory Board

May 14, 2007 - Upstream Biosciences Inc. (OTCBB:UPBS) ("Upstream" or "the Company"), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced today the appointment of Mr. Edward Kiruluta to its scientific advisory board. Mr. Kiruluta is currently Vice President, Engineering at DemandTec where he leads the econometrics, optimization research, and database teams and prior to joining DemandTec, Mr. Kiruluta was Senior Director of Informatics at Merck Research Labs (MRL) where he led the development of the Target Genome Index (TGI), an environment to help researchers gain better insights into biological function and drug response by integrating clinical data with genomics, proteomics and metabolomics technologies.

Prior to joining Merck, Mr. Kiruluta was Chief Technology Officer and Vice President, R&D at DoubleTwist (formerly Pangea Systems). At DoubleTwist, Mr. Kiruluta led the team of scientists and engineers to develop Prophecy, the history-making, first comprehensive annotation of the human genome, and DoubleTwist.com, the first portal for life science researchers. Mr. Kiruluta has over 15 years of experience in the software and life science industries.

"While assembling our team at DoubleTwist, Dexster and I recruited and hired Edward to provide the key leadership of our scientists and engineers which was essential for the development of our ground breaking and proprietary product. Edward was a big part of our highly successful and world renowned bioinformatics initiative to be the first to successfully assemble and annotate the human genome. We believe Edward will positively contribute to the further development of Upstream’s diagnostic tests and his relationships with major pharmaceutical companies will benefit us as we move through our licensing process,” said Upstream CEO Joel Bellenson.

Upstream is developing diagnostic tests that may aid in the early detection of cancer by identifying individuals with disease susceptibility. Upstream is also developing diagnostic tests that may determine whether a drug will be useful or harmful to an individual patient based on their genetic profile. According to the Journal of the American Medical Association, each year 100,000 people die in the United States due to adverse reactions to prescription drugs.

For more information, please contact Samantha Haynes at 1-800-539-0289 or .

Media Contact: David Libby, Libby Communications: Tel. 510.868.4903 / Cel. 510.377.1466 or .

» BACK

About Upstream Biosciences Inc.
Upstream Biosciences Inc. is an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response founded in 2004. Upstream discovers, develops, and licenses genetic based diagnostics for cancer susceptibility and drug response. Upstream's proprietary data mining pipeline enables it to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene, the 'gene switches,’ which control the quantities and timing of expression of the genes and proteins important to disease and drug response.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements", as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among others, the expectation and/or claim, as applicable, that: (i) the Company may become an emerging leader in the field of diagnostics for cancer and the prediction of drug response; (ii) the Company is developing diagnostic tests that may aid in the early detection of cancer by identifying individuals with disease susceptibility; (iii) the Company is developing diagnostic tests that may determine whether a drug will be useful or harmful to an individual patient based on their genetic profile; (iv) the Company may discover, develop and license its genetic based diagnostics for cancer susceptibility and drug response; and (v) the Company’s data mining pipeline may enable the Company to locate and analyze genetic variations in the regions of DNA which control the quantities and timing of expression of the genes and proteins important to disease and drug response.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that the Company does not execute its business plan; (ii) the inability of the Company to keep pace with technological advancements in the field of genetic diagnostics; (iii) the Company's inability to adequately protect its intellectual property or the Company's inadvertent infringement of third party intellectual property; (iv) the Company not being able to retain key employees; (v) competitors providing better or cheaper products and technologies; (vi) markets for the Company's products not developing as expected; (vii) the Company's inability to finance its operations or growth; (viii) inability to obtain all necessary government and regulatory approvals; and (ix) the inability to effectively market and commercialize the Company's technologies, including the establishment of viable relationships with third parties. These forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company's periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.

DISCLAIMER FOR HISTORICAL PRESS RELEASES AND SEC FILINGS This section contains historical and archived press releases and SEC filings for Upstream Biosciences Inc. The information in these press releases and SEC filings is historical in nature, has not been updated, and is current only to the date indicated in the particular press release or SEC filing. This information may no longer be accurate and therefore you should not rely on the any information contained in these press releases or SEC filings and should refer to our latest press releases and SEC filings. To the extent permitted by law, Upstream Biosciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.